IFN

Protara Therapeutics Announces Trials in Progress Poster Presentation for the ADVANCED-1 Trial in NMIBC at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Thursday, May 26, 2022
Online, Cancer, U.S. Securities and Exchange Commission, TNF, Private Securities Litigation Reform Act, Food, Streptococcus pyogenes, LMS, Bladder cancer, Nasdaq, Food and Drug Administration, Patient, Cyst, Therapy, IL-8, Degenerative disease, Cytokine, Microcystic lymphatic malformation, Society, CIS, IFN, COVID-19, LM, Streptococcus, FDA, Neutrophil, Industry, Granulocyte-macrophage colony-stimulating factor, Safety, Neoplasm, NMIBC, Lymphocyte, IL-12, Monocyte, IL-6, Granulocyte colony-stimulating factor, United, GLOBE, Medical imaging, Pharmaceutical industry

The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • The ADVANCED-1 study is evaluating TARA-002, an investigational cell-based immunopotentiator, for the treatment of non-muscle invasive bladder cancer (NMIBC).
  • We look forward to continuing to advance this trial and exploring TARA-002s full potential in NMIBC.
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer inthe United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.

Tonix Pharmaceuticals Extends Research Collaboration with the University of Alberta to Develop Antiviral Drugs Against SARS-CoV-2

Retrieved on: 
Wednesday, May 18, 2022
Department, University of Alberta, Severe acute respiratory syndrome coronavirus 2, Cell biology, Peroxisome, Prader–Willi syndrome, Pain, Company, SL, Long COVID, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Cocaine, Disease, Nasdaq, Autoimmunity, Degenerative disease, Monkeypox, Vaccine, Government, Coronavirus, Psychiatry, Hydrogen chloride, IFN, COVID-19, Failure, Cell, Fibromyalgia, Research, FDA, CNS, Infection, Smallpox, Virus, Orthornavirae, RNA, CD154, Technology, Central nervous system, Neurology, University, III, Risk, Therapy, SEC, Cancer, Security (finance), Annual report, GLOBE, Pharmaceutical industry, Professor, Tonix Pharmaceuticals

Antiviral therapeutics are needed to mitigate the effects of SARS-CoV-2 and future coronavirus outbreaks, and Professor Hobmans work is designed to facilitate the identification and testing of novel broad-spectrum antiviral drugs.

Key Points: 
  • Antiviral therapeutics are needed to mitigate the effects of SARS-CoV-2 and future coronavirus outbreaks, and Professor Hobmans work is designed to facilitate the identification and testing of novel broad-spectrum antiviral drugs.
  • SARS-CoV-2 is very sensitive to interferon (IFN) treatment and therefore, drugs that upregulate IFN production and/or signaling may reduce virus replication.
  • The research collaboration is focused on the development and testing of Wnt/-Catenin signaling pathway inhibitors as broad-spectrum antivirals against SARS-CoV-2 and other emerging viruses, said Professor Tom Hobman.
  • Peroxisomes are key antiviral signaling platforms that are important for IFN induction and antiviral defense.

Obsidian Therapeutics to Present Significant Advancements to its Proprietary cytoDRiVE® Technology at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2022

Retrieved on: 
Tuesday, May 17, 2022
Risk, Engineering, Company, IL2, Vertex Pharmaceuticals, TILS, Patient, Therapy, Cytokine, IL23, IFN, List of Farscape characters, Bristol Myers Squibb, IL12, FDA, Convention center, Biotechnology, Toxicity, Technology, Abstract (summary), LinkedIn, Twitter, Vaccine, Obsidian

CAMBRIDGE, Mass., May 17, 2022 /PRNewswire/ -- Obsidian Therapeutics, Inc., a biotechnology company pioneering engineered cell and gene therapies, today announced it will present enhancements to its proprietary cytoDRIVE® technology during a poster presentation at the 25th ASGCT Annual Meeting. The conference is being hosted in Washington, D.C., and virtually, May 16-19, 2022.

Key Points: 
  • Design elements such as membrane-tethering to reduce risk of systemic toxicity and engineering of protease sites for controlled shedding enable fit-for-purpose engineering and potential to regulate multiple cytokines.
  • Obsidian Therapeutics, Inc. is a biotechnology company pioneering engineered cell and gene therapies to deliver transformative outcomes for patients with intractable diseases.
  • Obsidian's proprietary cytoDRiVE technology provides a way to precisely control the timing and level of protein function by using FDA approved small molecules.
  • For more information, please visit www.obsidiantx.com and follow us on LinkedIn and Twitter .

Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus

Retrieved on: 
Monday, May 9, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dermatomyositis, NLRP3, COVID-19, Scar, SLE, RNA, Pain scale, National Center for Advancing Translational Sciences, IFN, UVB, U.S. Department of Defense Strategy for Operating in Cyberspace, Sunlight, Â, Tooth discoloration, Patient, DNA, DM, Infant, Inflammation, LRP, Hypersensitivity, Human, Bureau of Oceans and International Environmental and Scientific Affairs, Therapy, Industry, Cytoplasm, Lupus, AGS, Neurology, Veteran, Quality of life, LinkedIn, Disease, Rockefeller University, Hair loss, Molecular biology, Technology, Protein, Research, Resolve, CXCL10, CLE, United States Department of Defense, DOD, Pharmaceutical industry, Vaccine, Ventus

The multi-year grant will be used to study the role of the DNA sensor, cyclic GMP-AMP synthase (cGAS), in lupus and the potential for treatment using a cGAS inhibitor.

Key Points: 
  • The multi-year grant will be used to study the role of the DNA sensor, cyclic GMP-AMP synthase (cGAS), in lupus and the potential for treatment using a cGAS inhibitor.
  • Systemic Lupus Erythematosus (SLE) is a chronic multi-organ auto-inflammatory disease for which there remains a high unmet medical need.
  • This susceptibility affects up to 70% of patients and can result in painful skin lesions that cause scarring, hair loss and discoloration.
  • The Lupus Research Program (LRP) was initiated in 2017 to provide support for research of exceptional scientific merit leading to a cure for lupus.

Shionogi and NEC Enter into Strategic Research Collaboration for Novel Hepatitis B Therapeutic Vaccine

Retrieved on: 
Monday, April 18, 2022
Hepatitis, Biotechnology, Recurrence, Cancer, Hepatitis B, Hepatitis B virus, COVID-19, NEC, HBV, Research, Immunotherapy, Diagnosis, Descriptive ethics, Interferon, Incidence, Infection, Drug discovery, Death, Patient, IFN, Artificial intelligence, Efficiency, National Exhibition Centre, Global health, Technology, AI, Chronic condition, Shionogi, Safety, Cirrhosis, Partnership, Liver cancer, Pharmaceutical industry, Vaccine

OSAKA, Japan and TOKYO, Japan, Apr 18, 2022 - (JCN Newswire) - Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine.

Key Points: 
  • OSAKA, Japan and TOKYO, Japan, Apr 18, 2022 - (JCN Newswire) - Shionogi & Co., Ltd. and NEC Corporation, today announced the execution of a strategic research collaboration agreement for the development of a novel hepatitis B therapeutic vaccine.
  • NEC OncoImmunity, an NEC subsidiary that specializes in artificial intelligence-driven biotechnology, is also participating in this research collaboration.
  • Hepatitis B is a potentially life-threatening liver disease caused by the hepatitis B virus (HBV).
  • About 300 million people are living with chronic hepatitis B infection worldwide, and hepatitis B resulted in an estimated 820,000 deaths in 20191.

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

Retrieved on: 
Thursday, April 7, 2022
Company, Compugen (Israeli company), Therapy, Private Securities Litigation Reform Act, NASDAQ, Partnership, Investigational New Drug, Toxicity, Neuroscience, Jazz Pharmaceuticals, IND, Tumor microenvironment, Research, SEC, Risk, Commission, Cancer, Food, U.S. Securities and Exchange Commission, Neoplasm, Security (finance), IFN, Immune system, Technology, Twitter, Vision 2025, Medication, Society, Nasdaq, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Jazz, Toxic epidermal necrolysis, ASH, NK, FDA, Terminology, Annual report, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Risk management, Werewolf

DUBLIN and CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Werewolf Therapeutics, Inc. (Nasdaq: HOWL) today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.

Key Points: 
  • Jazz expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for WTX-613 in 2023.
  • "We are thrilled to join forces with Jazz to advance WTX-613 on behalf of patients," said Daniel J. Hicklin, Ph.D., president and chief executive officer of Werewolf.
  • Under the terms of the transaction, Jazz has secured exclusive global rights to WTX-613.
  • Jazz Pharmaceuticals plc(NASDAQ: Jazz) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE™ Molecule

Retrieved on: 
Thursday, April 7, 2022
Company, Compugen (Israeli company), Therapy, Private Securities Litigation Reform Act, NASDAQ, Partnership, Investigational New Drug, Toxicity, Neuroscience, Jazz Pharmaceuticals, IND, Tumor microenvironment, Research, SEC, Risk, Commission, Cancer, Food, U.S. Securities and Exchange Commission, Neoplasm, Security (finance), IFN, Immune system, Technology, Twitter, Vision 2025, Medication, Society, Nasdaq, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, Jazz, Toxic epidermal necrolysis, ASH, NK, FDA, Terminology, Annual report, Patient, Medical imaging, Pharmaceutical industry, Vaccine, Risk management, Werewolf

DUBLIN and CAMBRIDGE, Mass., April 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Werewolf Therapeutics, Inc. (Nasdaq: HOWL) today announced that the companies have entered into a licensing agreement under which Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule.

Key Points: 
  • Jazz expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for WTX-613 in 2023.
  • "We are thrilled to join forces with Jazz to advance WTX-613 on behalf of patients," said Daniel J. Hicklin, Ph.D., president and chief executive officer of Werewolf.
  • Under the terms of the transaction, Jazz has secured exclusive global rights to WTX-613.
  • Jazz Pharmaceuticals plc(NASDAQ: Jazz) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families.

Protara Therapeutics Doses First Patient in ADVANCED-1 Phase 1 Study of TARA-002 in Non-Muscle Invasive Bladder Cancer

Retrieved on: 
Thursday, March 24, 2022
Company, Private Securities Litigation Reform Act, Therapy, Cancer, Recurrence, Cyst, Cytokine, Microcystic lymphatic malformation, Interleukin, IL-8, Streptococcus pyogenes, Degenerative disease, LMS, LM, Neutrophil, Lymphocyte, Granulocyte colony-stimulating factor, NMIBC, University, Pathology, Chugai Pharmaceutical Co., Streptococcus, Neoplasm, IL-12, Food, Granulocyte-macrophage colony-stimulating factor, IFN, TNF, Industry, Safety, CIS, Food and Drug Administration, Nasdaq, COVID-19, GLOBE, U.S. Securities and Exchange Commission, Bladder cancer, IL-6, FDA, Monocyte, Patient, Pharmaceutical industry, Medical imaging

In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.

Key Points: 
  • In the initial dose escalation phase of the trial, patients will receive six weekly intravesical doses of TARA-002.
  • Bladder cancer is the 6th most common cancer in the United States, with NMIBC representing approximately 80% of bladder cancer diagnoses.
  • NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle.
  • Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.

Kymera Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

Retrieved on: 
Thursday, February 24, 2022
Risk, HS, NYU, SAD, Security (finance), COVID-19, Hidradenitis suppurativa, Therapy, Sanofi, Company, AD, Private Securities Litigation Reform Act, Research, Lymphoma, Development, Apoptosis, Degenerative disease, MDM2, Growth, Investment, Atopic dermatitis, Lymphatic system, Safety, Disease, U.S. Securities and Exchange Commission, Skin, Drug discovery, Goal, CEO, Autoimmunity, Program, Cash, Doctor of Philosophy, Entrepreneurship, Completeness, NASDAQ, Administration, PBMC, Controlled Impact Demonstration, Cancer, Rheumatoid arthritis, Patient, Immunomodulatory imide drug, GLOBE, IFN, University, Annual report, STAT3, Biology, RA, FDA, MAD, University of Washington Department of Global Health, Vaccine, Pharmaceutical industry, Fine chemical, Animal, Video game, Black Majesty, IND, Vertex, IRAK4

Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.

Key Points: 
  • Kymera is collaborating with Sanofi on the development of degrader candidates targeting IRAK4, including KT-474 (SAR444656), outside of the oncology and immune-oncology fields.
  • In 4Q of 2021, Kymera nominated KT-253, its first-in-class MDM2 degrader as development candidate, which is now in IND enabling activities.
  • Cash and Cash Equivalents: As of December 31, 2021, Kymera had approximately $567.6 million in cash, cash equivalents, and investments.
  • Kymera Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Provectus Biopharmaceuticals Provides Update on Research into PV-10® Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better

Retrieved on: 
Thursday, January 27, 2022
Microbiology, Family, Vaccine, Forward-looking statement, HBV, Vaccination, Virus, Peptide, Research, Ophthalmology, OTCQB, Hematology, National, Legislation, IFN, CD8, Patent, CD4, Virology, Company, Hepatitis B virus, Cancer, HBcAg, Dermatology, Hepatitis, Xanthene, NIH, Drug discovery, USPTO, Immunotherapy, GLOBE, Safety, Pharmaceutical industry

On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus patent application entitled Halogenated Xanthenes as Vaccine Adjuvants ( publication no.

Key Points: 
  • On January 20, 2022, the U.S. Patent and Trademark Office (USPTO) published Provectus patent application entitled Halogenated Xanthenes as Vaccine Adjuvants ( publication no.
  • Dominic Rodrigues, Vice Chair of the Companys Board of Directors, said, Immune adjuvants can help vaccines generate quicker, more efficacious and durable immune responses.
  • This new research further supports the multi-faceted immunogenicity of Provectus small molecule medical science platform, which is the foundation of our work to develop transformative, accessibly-priced immunotherapy medicines.
  • Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a family of small molecules called halogenated xanthenes.